Tango Therapeutics (TNGX)’ treatment of pancreatic cancer was granted FDA orphan designation, according to a post to the agency’s website.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics price target lowered to $8 from $16 at B. Riley
- Tango Therapeutics price target lowered to $8 from $18 at Guggenheim
- Tango Therapeutics Advances Cancer Treatment Pipeline
- Trump Media, broader market surge after Trump wins election: Morning Buzz
- Tango Therapeutics reports Q3 EPS (27c), consensus (37c)